[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100503568":3},{"organization":4,"outcomesModule":7,"designInfo":50,"detailedDescription":49,"studyPopulation":49,"armGroups":56,"interventions":63,"overallOfficials":49,"centralContacts":68,"locations":77,"responsibleParty":97,"collaborators":49,"id":99,"slug":49,"hasResults":100,"nctId":101,"briefTitle":102,"officialTitle":103,"acronym":49,"eligibilityCriteria":104,"healthyVolunteers":100,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":49,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":49,"overallStatus":80,"whyStopped":49,"lastUpdateSubmitDate":117,"lastUpdatePostDateStruct":118,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":126},{"fullName":5,"class":6},"Shanghai Hengrui Pharmaceutical Co., Ltd.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":20,"otherOutcomes":49},[9,13,17],{"measure":10,"description":11,"timeFrame":12},"Maximum tolerated dose (MTD) or maximum administered dose (MAD)","Incidence and category of dose limiting toxicities (DLTs) during the first 4 week cycle of SHR-9839 treatment","On the first day of each week,4 weeks is a treatment cycle",{"measure":14,"description":15,"timeFrame":16},"Recommended Phase 2 dose (RP2D)","RP2D will be determined on the basis of evaluation on MTD\u002FMAD, PK, PD, efficacy data in dose escalation and dose expansion stages.","From Day 1 to 90 days after last dose",{"measure":18,"description":19,"timeFrame":16},"Incidence and severity of adverse events (AEs)\u002Fserious adverse events (SAEs) ([CTCAE] v5.0)","Assess safety and tolerability of SHR-9839 by way of adverse events (CTCAE v5.0).",[21,25,28,32,35,39,43,45,47],{"measure":22,"description":23,"timeFrame":24},"PK parameter: Tmax of SHR-9839","Time to maximum concentration of SHR-9839","approximately 10 months",{"measure":26,"description":27,"timeFrame":24},"PK parameter: Cmax of SHR-9839","Maximum concentration of SHR-9839",{"measure":29,"description":30,"timeFrame":31},"PK parameter: AUC0-t of SHR-9839","Area under the concentration-time curve from time 0 to the last measurable concentration time point of SHR-9839","Approximately 10 months",{"measure":33,"description":34,"timeFrame":31},"PK parameter: AUC0-∞ of SHR-9839","Area under the concentration-time curve from time 0 to infinity of SHR-9839",{"measure":36,"description":37,"timeFrame":38},"Immunogenicity of SHR-9839","Anti-SHR-9839 antibody (ADA)","Approximately 12 months",{"measure":40,"description":41,"timeFrame":42},"Overall response rate (ORR)","Evaluated using RECIST 1.1","Approximately within 36 months",{"measure":44,"description":41,"timeFrame":42},"Duration of response (DoR)",{"measure":46,"description":41,"timeFrame":42},"Disease control rate (DCR)",{"measure":48,"description":41,"timeFrame":42},"Progression-free survival (PFS)",null,{"allocation":51,"interventionModel":52,"interventionModelDescription":49,"primaryPurpose":53,"observationalModel":49,"timePerspective":49,"maskingInfo":54},"NA","SINGLE_GROUP","TREATMENT",{"masking":55,"maskingDescription":49,"whoMasked":49},"NONE",[57],{"label":58,"type":59,"description":60,"interventionNames":61},"SHR-9839","EXPERIMENTAL","three stages: dose escalation, dose expansion and efficacy expansion.",[62],"Drug: SHR-9839",[64],{"type":65,"name":58,"description":66,"armGroupLabels":67,"otherNames":49},"DRUG","Weekly fixed dose injection of SHR-9839",[58],[69,74],{"name":70,"role":71,"phone":72,"phoneExt":49,"email":73},"Rongfu Mao, MD","CONTACT","+86 021-61053363","rongfu.mao@hengrui.com",{"name":75,"role":71,"phone":72,"phoneExt":49,"email":76},"Jin Wang, COD","jin.wang@hengrui.com",[78],{"facility":79,"status":80,"city":81,"state":82,"zip":83,"country":84,"countryCode":85,"cosmosGeoPoint":86,"geoPoint":91,"contacts":92},"Zhejiang Tumor Hospital","RECRUITING","Hangzhou","Zhejiang","310006","China","CN",{"type":87,"coordinates":88},"Point",[89,90],120.16142,30.29365,{"lat":90,"lon":89},[93],{"name":94,"role":71,"phone":95,"phoneExt":49,"email":96},"Xiangdong Cheng, Doctor","+86-13968032995","Chengxd516@126.cm",{"type":98,"investigatorFullName":49,"investigatorTitle":49,"investigatorAffiliation":49,"oldNameTitle":49,"oldOrganization":49},"SPONSOR","100503568",false,"NCT05836948","The Clinical Study of SHR-9839 for Injection in Patients With Advanced Solid Tumors","An Open-label, Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-9839 for Injection in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n1. Patients with histologically or cytologically confirmed unresectable locally advanced or metastatic solid tumors which is relapsed or refractory to standard treatment, or lack of standard treatment, or standard treatment is not applicable currently;\n2. Have at least one measurable tumor lesion per RECIST v1.1;\n3. ECOG performance status of 0-1;\n4. Life expectancy ≥ 12 weeks;\n5. Adequate bone marrow and organ function;\n6. Subjects must voluntarily agree to participate in the trial and sign a written informed consent form.\n\nExclusion Criteria:\n\n1. Patients with active central nervous system metastases or meningeal metastases;\n2. Received anti-tumor treatment such as chemotherapy, biotherapy, targeted therapy, immunotherapy, radical radiotherapy, or other unlisted clinical research drugs or treatments within 4 weeks prior to the first use of the study drug;\n3. History of serious cardiovascular and cerebrovascular diseases;\n4. Subjects who received\\>30Gy of radiation therapy within 4 weeks before the first medication, and those who received ≤ 30Gy of palliative radiation therapy within 7 days before the first medication;\n5. Adverse reactions of previous anti-tumor treatment have not recovered to Grade ≤ 1 per NCI-CTCAE v5.0.","ALL","18 Years","70 Years",{"count":109,"type":110},174,"ESTIMATED","INTERVENTIONAL",[113],"PHASE1","This study is an open-label, phase I clinical trial of SHR-9839 in patients with advanced solid tumors. The whole study is divided into three stages: dose escalation, dose expansion and efficacy expansion.",[116],"Advanced Solid Tumor","2025-08-08",{"date":119,"type":120},"2025-08-11","ACTUAL",{"date":122,"type":120},"2023-05-18",{"date":124,"type":110},"2026-06-01",{"name":5,"class":6},1]